Product Liability Lawyer Blog

February 25, 2015

Sexual Dysfunction May Cause Low T, Rather Than Be Result of It

Of the many claims made by drug companies regarding testosterone replacement therapy (TRT) products is they can help patients with decreased sexual desire or performance caused by low testosterone levels.

While doctors do not know what a testosterone level should be in “normal” patients, and also do not know whether having a lower than average testosterone level is a medical problem for most adults, drug companies created the term “Low T” and push for use of testosterone replacement therapy drugs to fix what they consider a problem.

However, new research shows a decreased desire to have sex may actually cause lower testosterone levels rather than lower testosterone levels resulting in a decrease in one’s desire to have sex or erectile dysfunction (ED), according to a recent article from Scientific American.
Continue reading

February 22, 2015

Unapproved Knee Replacement Device Used in Surgery

by Jeffrey S. Glassman

When we go to the doctor for a major surgical procedure such as a total knee replacement, we assume our doctor will use the latest devices and techniques. However, we also assume any equipment used will have been subject to clinical trials and approved by the United States Food and Drug Administration (FDA).

Unfortunately, according to a recent news article from the New York Times, things don’t always work out so well. One patient interviewed for a story was scheduled to undergo a total knee replacement procedure.

When a surgeon performs a total knee replacement, he or she relies on a medical device known as a cutting guide. Much like a carpenter’s jig, a surgical cutting guide is placed on the bone to be cut so the surgeon knows where to apply his or her bone saw. Cuts must be made in the precision location to increase the chances of a proper fit and alignment. If alignment is off, even slightly, patients can have a longer recovery, increased pain, decreased range of movement, and in worst cases, the artificial knee may fail and become loose or dislodged.
Continue reading

February 19, 2015

McClellan v. I-Flow Corp. – Pain Pump Litigation to Continue

by Jeffrey S. Glassman

In recent years, product liability lawyers have seen a growing number of injuries filed by individuals who developed severe cartilage damage in their shoulders following minimally invasive surgery.

The suspected culprit is a type of shoulder “pain pump” used to deliver medication directly into the joint after surgical joint procedures. Usually, the device is filled with various pain medications, and the idea is to deliver the medication quickly and directly to the site of surgery.

Problematically, this procedure has been linked to the development of a debilitating condition known as chondrolysis. This means there is virtually no cartilage between the bones, and joints can become fused and completely immobile. Usually, by the time the condition is discovered and diagnosed, there is no treatment or cure. The condition is typically discovered between three and 12 months after surgery.
Continue reading

February 17, 2015

Boston Toy Injuries: 40 Percent Increase in 22 Years

by Jeffrey S. Glassman

The number of toy-related injuries in the U.S. has spiked by a stunning 40 percent over the past 25 years, and researchers say that’s likely a low-ball estimate.

According to a new study published by the journal Clinical Pediatrics, over 3 million children were treated in hospital emergency departments between 1990 and 2011. But what’s especially troubling is the fact the rate at which injuries occurred increased steadily during that time.

Today, a child is treated in a hospital emergency room every three minutes for a toy-related injury. Of those, more than half are younger than the age of six.
Continue reading

February 15, 2015

2014 Had Highest Auto Recall Numbers in U.S. History

by Jeffrey S. Glassman

With the recent announcement by the National Highway Traffic Safety Administration that another 2.1 million vehicles are recalled due to faulty crash sensors that could result in sudden and unnecessary airbag deployment, we see a continuation of what was an especially awful year for the auto industry – and consumers.

Reports are that 2014 was a record year for auto recalls in the U.S., with 60 million vehicles recalled between Jan. 1 and Dec. 30. That is more than twice as many as the previous annual record number of recalls, which was set in 2004.

With a total of 700 vehicle recall announcements last year, it averaged out to about two every day, with one in five vehicles on the road affected.
Continue reading

February 10, 2015

New Procedure Potential Alternative to Total Hip Replacement Surgery

by Jeffrey S. Glassman

Total hip replacement surgeries in the United States have increased by astonishing rates over the past decade. Medical device manufacturers have been heavily marketing new artificial hips to surgeons and patients as a way to get rid of the pain of arthritis and allow people to function as they did when they were years younger.

While many patients actually need a new hip, many may not. Additionally, regardless of the need for a total hip replacement, no patient needs to be victim to one of the numerous defective hips and surgical cutting guides that have hit the market. Victims have suffered extreme pain and suffering, partial or complete failures of their new artificial hips, and other serious health conditions related to a defectively designed medical device.

According to a recent news article from the Daily Mail, doctors in England are in clinical trials with a new technique they hope will one day lead to an end to total hip replacement surgery. This new technique uses an experimental product called Preob, which is called an osteoblastic (bone-forming) agent.
Continue reading

February 5, 2015

FDA Intervenes When New Testosterone Drug Causes Side Effects

by Jeffrey S. Glassman

For most of the past decade, it has become impossible to watch a sporting event on television without being inundated with advertisements for testosterone replacement therapy (TRT) drugs. While the United States Food and Drug Administration (FDA) has only approved testosterone replacement therapy drugs to treat an extremely rare condition known as hypogonadism, drug companies have created a new market for their once seldom used product.

The marketing divisions of several major drug companies have convinced aging men that by taking TRT drugs, it will help them overcome fatigue, mild depression, weight gain, loss of muscle tone, loss of libido and other characteristics of normal male aging. Drug companies claim these characteristics are really symptoms of having a low testosterone level or “Low-T”, as it is called by drug companies. They correctly figured men would be comfortable saying they are concerned about Low-T than they are about having low testosterone.
Continue reading

February 1, 2015

Philadelphia Judge Certifies Xarelto Lawsuits for Mass Tort Docket

by Jeffrey S. Glassman

Xarelto is a relatively new type of blood-thinning medication in a class of drugs called New Oral Anticoagulants (NOACs).

Xarelto is manufactured by Bayer AG and sold in the United States with Bayer’s marketing partner, Janssen Pharmaceuticals. Janssen is a subsidiary of Johnson & Johnson.

These companies market Xarelto for patients at high risk of developing serious clotting disorders such as stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE). A PE is deadly health condition in which a clot forms and then dislodges itself and travels through the circulatory system until it reaches the lungs. One in a lung, it can tear a hole in the tissues, causing serious illness or death.

Patients at risk for these conditions normally require a blood thinner such as Warfarin. While Warfarin is generally effective, patients must closely watch their diet and have regular blood tests to control their dosage. If the dosage is off, patients can develop life-threatening side effects. Xarelto, on the other hand, is supposed be as effective without requiring constant dose monitoring.
Continue reading

January 26, 2015

Flyers Defenseman Kimmo Timonen Taking Xarelto to Help Get Back on Ice

by Jeffrey S. Glassman

Philadelphia flyers Defenseman, Kimmo Timonen hopes to recover from a serious clotting disorder to a point, which will allow him to get back on the ice. According to a recent news article from Courier-Post, Timonen has been unable to play this season after being diagnosed with blood clots in his lungs and legs.

As part of his treatment for his serious clotting disorder, Timonen has been taking Xarelto. Xarelto is a member of a class of drugs known as New Oral Anticoagulants (NOACs). NOACs are a newer alternative to traditional blood thinners such as Warfarin. Those with clotting disease are at a high risk for stroke if one of the clots breaks free from a vein and block an artery providing blood to patient’s brain. Clots can also travel to patient’s lungs and tear a hole known as a pulmonary embolism (PE). Both of these can result in serious personal injury or death.

One advantage touted by makers of Xarelto is patients are not required to have frequent blood tests, and closely monitor their diets to keep their dosage in check. If Warfarin is administered in an incorrect dosage, it can cause life-threatening side effects. Doctors will use results of frequent blood tests to adjust a patient’s dosage from time to time.
Continue reading

January 24, 2015

New Injection May help Reduce Pain of Total Knee Replacement Surgery

by Jeffrey S. Glassman

Even a completely successful knee replacement surgery procedure will involve a great deal of pain and suffering as the patient heals from his or her wound and builds up strength.

According to a recent news article from HCP Live, a new injectable medication administered during total knee replacement surgery may help alleviate much of the pain following surgery.

The new drug being studied is called liposomal bupivacaine, and is injected into tissue surrounding the knee during total knee replacement surgery. Researchers hope it will provide considerable relief from pain expected to follow surgery.

Researchers note pain from the injection is comparable to pain from knee replacement surgery and has been shown in studies to provide patients with up to two days of pain relief following surgery. These two days of pain relief have allowed patients to use their new knee sooner, which can greatly decrease recovery time.
Continue reading